Due to the nature of NPM1-mutated AML, with the driving factor being an oncoprotein, immunotherapy is an ideal approach that focuses on either targeting mutant NPM1-derived neoantigens or genetically engineering T cells specific for NPM1-mutated peptides. This evidence concerns the gene NPM1 and acute myeloid leukemia.